Scarica l'app Stockscreener
2.82
4.44%
0.12
Dopo l'orario di chiusura:
2.82
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
Analysts see significant upside in C4 Therapeutics (CCCC) stock - msn.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - sahmcapital.com
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Director at C4 Therapeutics (NASDAQ: CCCC) granted 4,259 shares - Stock Titan
Director at C4 Therapeutics (NASDAQ: CCCC) takes stock pay - Stock Titan
New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is C4 Therapeutics (CCCC) stock outpacing its medical peers this year? - MSN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
C4 Therapeutics, Inc. advances pipeline as SVP Shagha Russell drives cemsidomide toward regulatory studies - Traders Union
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics begins trial of cemsidomide with elranatamab - Investing.com
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - The Manila Times
C4 Therapeutics Announces First Patient Dosed in Phase 1b - GlobeNewswire
Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock - Insider Monkey
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma - bitget.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Shorts: Is C4 Therapeutics Inc currently under institutional pressureGap Down & Expert Approved Momentum Ideas - baoquankhu1.vn
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab - MarketBeat
Are you looking for a top momentum pick? Why C4 Therapeutics, Inc. (CCCC) is a great choice - MSN
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact (NASDAQ:CCCC) - Seeking Alpha
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):